Ruthenium(II) p-cymene complex bearing 2,2'-dipyridylamine targets caspase 3 deficient MCF-7 breast cancer cells without disruption of antitumor immune response.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Inorganic Biochemistry

• Publication date

  2015-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.jinorgbio.2015.09.006PMID 26428537
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Binuclear dichlorido(η6-p-cymene)ruthenium(II) complexes with bis(nicotinate)- and bis(isonicotinate)-polyethylene glycol ester ligands: Binuclear Ru(II) complexes with nicotinate and isonicotinate esters

  2015cited by this paper
• In vitro effects of binuclear (η6-p-cymene)ruthenium(II) complex containing bridging bis(nicotinate)-polyethylene glycol ester ligand on differentiation pathways of murine Th lymphocytes activated by T cell mitogen

  2015cited by this paper
• Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence

  2014cited by this paper
• Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes.

  2014cited by this paper
• Expanding Roles for CD4 T Cells and Their Subpopulations in Tumor Immunity and Therapy

  2013cited by this paper
• Cationic arene ruthenium(II) complexes with chelating P-functionalized alkyl phenyl sulfide and sulfoxide ligands as potent anticancer agents.

  2013cited by this paper
• Novel Ruthenium(II) and Gold(I) NHC Complexes: Synthesis, Characterization, and Evaluation of Their Anticancer Properties

  2013cited by this paper
• MYCN and the epigenome

  2013cited by this paper
• Biological activity of neutral and cationic iridium(III) complexes with κP and κP,κS coordinated Ph₂PCH₂S(O)xPh (x = 0-2) ligands.

  2013cited by this paper
• Role of IL-17 in Glioma Progression.

  2013cited by this paper
• On the Discovery, Biological Effects, and Use of Cisplatin and Metallocenes in Anticancer Chemotherapy

  2012cited by this paper
• Novel octahedral Pt(IV) complex with di-n-propyl-(S,S)-ethylenediamine-N,N'-di-2-(3-cyclohexyl)propanoato ligand exerts potent immunomodulatory effects.

  2012cited by this paper
• Anticancer metallotherapeutics in preclinical development.

  2011cited by this paper
• Expression of Th17 Cells in Breast Cancer Tissue and Its Association with Clinical Parameters

  2011cited by this paper
• Th-1 Lymphocytes Induce Dendritic Cell Tumor Killing Activity by an IFN-γ–Dependent Mechanism

  2011cited by this paper
• IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors

  2011cited by this paper
• Cancer treatments transform residual cancer cell phenotype

  2011cited by this paper
• Granzymes in cancer and immunity

  2010cited by this paper
• Towards selective ethylene tetramerization.

  2010cited by this paper
• Ruthenium(II)-arene complexes with functionalized pyridines: synthesis, characterization and cytotoxic activity.

  2010cited by this paper
• Synthesis, characterization and reactivity of arene ruthenium compounds based on 2,2′-dipyridylamine and di-2-pyridylbenzylamine and their applications in catalytic hydrogen transfer of ketones

  2010cited by this paper
• Protumor vs Antitumor Functions of IL-171

  2009cited by this paper
• Synthesis, characterization, in vitro antitumoral investigations and interaction with plasmid pBR322 DNA of R2eddp-platinum(IV) complexes (R = Et, n-Pr).

  2009cited by this paper
• Influence of Structural Variation on the Anticancer Activity of RAPTA-Type Complexes: ptn versus pta

  2009cited by this paper
• Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA

  2009cited by this paper
• Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.

  2009cited by this paper
• Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity.

  2009cited by this paper
• Multiple roles for CD4+ T cells in anti‐tumor immune responses

  2008cited by this paper
• Ruthenium(III) chloride complex with a tridentate bis(arylimino)pyridine ligand: synthesis, spectra, X-ray structure, 9-ethylguanine binding pattern, and in vitro cytotoxicity.

  2008cited by this paper
• The "complex-in-a-complex" cations [(acac)2M subset Ru6(p-iPrC6H4Me)6(tpt)2(dhbq)3]6+: A trojan horse for cancer cells.

  2008cited by this paper
• Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound.

  2008cited by this paper
• Influence of the Spacer Length on the in Vitro Anticancer Activity of Dinuclear Ruthenium−Arene Compounds

  2008cited by this paper
• Catalytic organometallic anticancer complexes

  2008cited by this paper
• In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands.

  2008cited by this paper
• Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents.

  2008cited by this paper
• New trends for metal complexes with anticancer activity.

  2008cited by this paper
• Water-Soluble Mixed-Ligand Ruthenium(II) and Osmium(II) Arene Complexes with High Antiproliferative Activity

  2008cited by this paper
• Synthesis, characterization and DNA binding properties of oligopyridine-ruthenium(II)-amino acid conjugates.

  2007cited by this paper
• Developing new metal-based therapeutics: challenges and opportunities.

  2007cited by this paper
• The design of organometallic ruthenium arene anticancer agents

  2007cited by this paper
• From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

  2006cited by this paper
• Paradoxical roles of the immune system during cancer development

  2006cited by this paper
• In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.

  2005cited by this paper
• KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development--an overview.

  2005cited by this paper
• Aloe-emodin prevents cytokine-induced tumor cell death: the inhibition of auto-toxic nitric oxide release as a potential mechanism

  2004cited by this paper
• A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

  2004cited by this paper
• The three Es of cancer immunoediting.

  2004cited by this paper
• In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer

  2002cited by this paper
• [Ru(η6-p-cymene)Cl2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo- [3.3.1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells

  2001cited by this paper
• Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis.

  2001cited by this paper
• Inhibition of cancer cell growth by ruthenium(II) arene complexes.

  2001cited by this paper
• IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

  2001cited by this paper
• Deficiency of caspase-3 in MCF7 cells blocks Bax-mediated nuclear fragmentation but not cell death.

  2001cited by this paper
• Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice.

  2000cited by this paper
• Ruthenium-based compounds and tumour growth control (review).

  2000cited by this paper
• Cis-platinum-induced immunosuppression: relationship to melatonin in human peripheral blood mononuclear cells.

  1999cited by this paper
• Assays related to cancer drug discovery

  1999cited by this paper
• The role of CD4+ T cell responses in antitumor immunity.

  1998cited by this paper
• Diphenylphosphino(phenylthio)methane as a monodentate or bidentate chelate ligand in rhodium, iridium and ruthenium complexes, 3rystal structure of [(η5-C5Me5) IrCl(η2-Ph2PCH2SPhP,S)]BF4·Me2CO

  1997cited by this paper
• Antimetastatic action and toxicity on healthy tissues of Na[trans-RuCl4(DMSO)Im] in the mouse

  1994cited by this paper
• Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

  1983cited by this paper
• Arene ruthenium(II) complexes formed by dehydrogenation of cyclohexadienes with ruthenium(III) trichloride

  1974cited by this paper

• Evaluation of phytochemical profiling, antioxidant and antimicrobial activities of Cionura erecta latex: the first report of the therapeutic potential of a natural exudate

  2025cites this paper
• Exploring the toxicity of mononuclear piano-stool Ru(II) anticancer agents: A comprehensive literature review

  2025cites this paper
• Fractionation of Essential Oils Extracted from Litsea angulata (Lauraceae) Using Two Different Methods and Their Impact on Lactic Acid Bacteria

  2025cites this paper
• Triphenyltin(IV) compounds bearing modulated azo-carboxylato ligands: Synthesis, structural characterization, in vitro cytotoxicity, BSA/DNA binding affinity, and in silico studies

  2024cites this paper
• Chemical profile and biological properties of the Piper corcovadense C.DC. essential oil

  2024cites this paper
• Ruthenium compounds: Are they the next‐era anticancer agents?

  2024cites this paper
• The impact of 9-azaglycophymine and phenylguanidine derivatives on the proliferation of various breast cancer cell lines in vitro and in vivo

  2024cites this paper
• Development of a nanoemulsion containing Lippia origanoides essential oil with antifungal activity by low energy method: from extraction to formulation

  2024cites this paper
• Individual and combined antifungal activities of Artemisia herba alba and Ammoides verticillata essential oils against the three main pathogenic microorganisms of potato.

  2023cites this paper
• Construction of homo and heteronuclear Ru(II), Ir(III) and Re(I) complexes for target specific cancer therapy

  2022cites this paper
• In Vitro Anticancer Screening and Preliminary Mechanistic Study of A-Ring Substituted Anthraquinone Derivatives

  2022cites this paper
• pH-Responsive Release of Ruthenium Metallotherapeutics from Mesoporous Silica-Based Nanocarriers

  2021cites this paper
• Health beneficial and pharmacological properties of p-cymene.

  2021cites this paper
• In Vitro Evaluation of Antiproliferative Properties of Novel Organotin(IV) Carboxylate Compounds with Propanoic Acid Derivatives on a Panel of Human Cancer Cell Lines

  2021influential citation
• Access to New Cytotoxic Triterpene and Steroidal Acid-TEMPO Conjugates by Ugi Multicomponent-Reactions †

  2021cites this paper
• Synthesis, antimicrobial and antiproliferative activities of new self-assembly benzimidazole-bridged aren ruthenium rectangles in human breast cancer cells

  2021cites this paper
• Chemical composition and combinatory antifungal activities of Ammoides verticillata, Allium sativum and Curcuma longa essential oils against four fungi responsible for Tomato Diseases.

  2020cites this paper
• Synthesis, characterization, DNA binding, cytotoxicity, and molecular docking approaches of Pd(II) complex with N,O- donor ligands as a novel potent anticancer agent

  2020cites this paper
• Synthesis, characterization and in vitro biological evaluation of novel organotin(IV) compounds with derivatives of 2-(5-arylidene-2,4-dioxothiazolidin-3-yl)propanoic acid.

  2020cites this paper
• Recent advances in cytotoxicity, cellular uptake and mechanism of action of ruthenium metallodrugs: A review

  2020cites this paper
• Recent Considerations in the Application of RAPTA‐C for Cancer Treatment and Perspectives for Its Combination with Immunotherapies

  2019cites this paper
• Ru(II)/N-N/PPh3 complexes as potential anticancer agents against MDA-MB-231 cancer cells (N-N = diimine or diamine).

  2019cites this paper
• Metallatranes and hydrometallatranes: their immunotropic and antitumor properties

  2019cites this paper
• Esterification of the free carboxylic group from the lutidinic acid ligand as a tool to improve the cytotoxicity of Ru(ii) complexes

  2019cites this paper
• C1-symmetrical cis-bis(di-2-pyridylamine)chloro(dimethyl sulfoxide-S)ruthenium(II) complex: Synthesis, crystal structure, and anion recognition using the NH groups in the chelating ligands

  2018cites this paper
• Metal Drugs and the Anticancer Immune Response.

  2018cites this paper
• Ruthenium(II)–Arene Metallacycles: Crystal Structures, Interaction with DNA, and Cytotoxicity

  2017cites this paper
• Update on Monoterpenes as Antimicrobial Agents: A Particular Focus on p-Cymene

  2017cites this paper
• Preparation and in vitro investigations of triphenyl[ω-(tetrahydro-2H-pyran-2-yloxy)alkyl]tin(IV) compounds

  2017cites this paper
• Antiproliferative activity of ruthenium(ii) arene complexes with mono- and bidentate pyridine-based ligands.

  2016cites this paper
• Half-Sandwich Ru(II) Halogenido, Valproato and 4-Phenylbutyrato Complexes Containing 2,2′-Dipyridylamine: Synthesis, Characterization, Solution Chemistry and In Vitro Cytotoxicity

  2016influential citation